CSF3 and acute myeloid leukemia: In agreement with the ELN guidelines, favorable-risk AML patients are commonly consolidated with autologous stem cell transplantation (ASCT) [2,8,9], and granulocyte colony-stimulating factors (G-CSF) are used to mobilize CD34+ stem cells from the bone marrow.